Perphenazine-d4

Perphenazine-d4 is the deuterium labeled Perphenazine. Perphenazine is a typical antipsychotic agent, inhibits 5-HT2Areceptor, Alpha-1A adrenergic receptor, Dopamine receptor D2/D3, D2L receptor, and Histamine H1 receptor, with Ki values of 5.6, 10, 0.765/0.13, 3.4, and 8 nM, respectively.

Product Specifications

CAS Number

[155593-75-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

5-HT Receptor; Adrenergic Receptor; Apoptosis; Autophagy; Dopamine Receptor; Histamine Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Field of Research

Neurological Disease; Endocrinology

Purity

99.0

Solubility

10 mM in DMSO|DMSO : 100mg/mL (ultrasonic)

Smiles

OCCN(CC1)CCN1CCCN2C3=C([2H])C(Cl)=C([2H])C=C3SC4=CC([2H])=CC([2H])=C42

Molecular Formula

C21H22D4ClN3OS

Molecular Weight

407.99

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. ; Richtand NM, et al. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007 Aug;32 (8) :1715-26.|[2]Richtand NM, et al. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology. 2007 Aug;32 (8) :1715-26.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.